Neuroleptic malignant syndrome (NMS) is a life threatening, though rare, complication of neuroleptic drugs. Patients suffering from this syndrome carry the A1 allele of the DRD2 gene, which is considered to reduce dopaminergic activity and glucose metabolism in regions of the brain with abundant dopamine receptors. These findings suggest the possibility that carriers of A1 show higher DRD2 blockade by neuroleptics and are more prone to develop NMS than non-carriers.
Genotype A1/A2 associated with neuroleptic malignant syndrome / M. DEL TACCA, L. Lattanzi, M. Lastella, A. DI PAOLO, F. Mungai, R. Danesi, F. Menichetti, L. Dell'Osso, G. Cassano. - In: BIPOLAR DISORDERS. - ISSN 1398-5647. - 7:4(2005), pp. 390-391. [10.1111/j.1399-5618.2005.00227.x]
Genotype A1/A2 associated with neuroleptic malignant syndrome
R. Danesi;
2005
Abstract
Neuroleptic malignant syndrome (NMS) is a life threatening, though rare, complication of neuroleptic drugs. Patients suffering from this syndrome carry the A1 allele of the DRD2 gene, which is considered to reduce dopaminergic activity and glucose metabolism in regions of the brain with abundant dopamine receptors. These findings suggest the possibility that carriers of A1 show higher DRD2 blockade by neuroleptics and are more prone to develop NMS than non-carriers.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
